SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Monday, June 6, 2016

Naveen Pemmaraju, MD, discusses early results from an ongoing trial of SL-401 in patients with the rare, aggressive malignancy blastic plasmacytoid dendritic cell neoplasm.

September 2017, Volume 3, Issue 11

August 2017, Volume 3, Issue 10

July Bonus Mid-Year Edition

July 2017, Volume 3, Issue 8

SL-401: An Encouraging Option for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Recent Articles

Hurricane Harvey Flooding Causes High Levels of Carcinogenic Substance

Senate Appropriations Committee Approves New Funding Bill for NIH and Opioid Crisis

High-Intensity Exercise Intervention Program in Myeloma Patients Who Received AHCT

Fertility Issues in Patients With Inherited Bone Marrow Failure Syndromes

With a Little Help From My Friends

Current Issue

September 2017, Volume 3, Issue 11

Meeting Coverage

CPX-351 Outperforms Induction Chemotherapy in Older High-Risk Patients With AML

Durable Response Observed With Pracinostat and Azacitidine for Older Patients With AML

Editor`s Corner

With a Little Help From My Friends

Meaningful Benefits